Illumina Introduces Genomics Solutions to Advance Clinical Research
October 07 2015 - 6:30AM
Business Wire
Scalable Workflow Solutions Optimized for NGS
and Microarrays
Illumina, Inc. (NASDAQ:ILMN) today announced the launch of new
TruSeq® library preparation kits and Infinium® arrays that enable
researchers to explore genetic variation on a more comprehensive
scale. The new additions to the application-driven portfolio
address a broad range of genetic studies from whole exome to
population and disease specific genotyping, leveraging the Illumina
industry-leading portfolio of genomic analysis systems. Illumina
will highlight these new genomic solutions at the 2015 American
Society of Human Genetics meeting on October 6 - 10 at Booth
#411.
“These solutions are designed to meet the needs of researchers
exploring diverse populations and diseases, enabling them to
cost-effectively navigate a wide continuum of study types ranging
from broad discovery to routine analysis,” said Francis deSouza,
President of Illumina.
The following new products are intended for use with Illumina
next-generation sequencing (NGS) systems and are complemented by
new data analysis applications available on Illumina’s BaseSpace
cloud computing platform.
TruSeq Enrichment Portfolio (TruSeq Exome and TruSeq
Rapid Exome Library Prep Kits) One of the most widely used
targeted sequencing methods is exome sequencing, allowing efficient
identification of coding variants across a broad range of studies
in cancer research, Mendelian disease and population genetics. The
TruSeq Exome kit is based on a shearing protocol, and the TruSeq
Rapid Exome kit is based on an enzyme-mediated (transposase)
protocol. The kits are compatible with a variety of sample types,
including formalin-fixed, paraffin-embedded (FFPE) samples, and
offer automation compatible, seamless workflows from sample to
variant calling.
TruSeq Custom Amplicon Low Input Designed and optimized
for use with FFPE samples, this new product consistently delivers
robust performance at 10ng of DNA input. Additional features
include a simplified, scalable workflow protocol and 16-sample
starter kit. Concurrently, Illumina is releasing an updated version
of DesignStudio™, its online custom assay design tool. Expert
design assistance and full assay optimization support is also
available through Illumina Concierge. Matched with Illumina’s
industry-leading sequencing systems, researchers can now achieve
robust data quality across genomic repeats and other
challenging-to-sequence regions of the genome.
The following new products are intended for use with Illumina’s
iScan® and HiScan® microarray platform. As with TruSeq Custom
Amplicon, these products can also be customized utilizing
DesignStudio or Illumina Concierge.
Infinium DrugDev Consortium Array Effective drug
development depends on thorough target validation and the
comprehensive understanding of drug safety and efficacy as early as
possible in the development process. Developed in collaboration
with leaders in translational genomics and computational biology,
the DrugDev Consortium Array enables researchers to perform genetic
studies leveraging the principle of Mendelian randomization to
reproduce key elements of a randomized trial. Key applications
include drug target discovery and validation, drug repurposing and
drug specificity studies.
Infinium MethylationEPIC BeadChip This is the
next-generation of the HumanMethylation450 BeadChip kit and
leverages new genetic content generated as a result of the National
Institutes of Health (NIH) sponsored ENCODE (Encyclopedia of DNA
Elements) research program. The new microarray provides
unparalleled coverage of CpG islands, GENCODE genes, ENCODE open
chromatin, ENCODE transcription factor binding sites and FANTOM5
enhancers. Infinium HD technology enables content selection
independent of bias often associated with alternative methylated
DNA capture methods. The new microarray is also compatible with
FFPE samples, offers a streamlined workflow and achieves 98 percent
reproducibility for technical replicates.
Infinium ImmunoArray-24 v2.0 BeadChip This is a new
addition to Illumina’s genotyping array portfolio and is designed
to detect genetic variation in the human immune system.
Applications include the research and analysis of novel and causal
variants associated with major autoimmune and inflammatory
disorders.
Infinium Multi Ethnic Array Family This provides a
cost-effective, high throughput approach for large scale population
research across diverse human populations. These new arrays
leverage expertly developed content from groups such as the
Consortium on Asthma among African-ancestry Populations in Americas
(CAAPPA), Population Architecture using Genomics and Epidemiology
(PAGE), and T2D-Genes, as well as large scale studies such as the
1,000 Genomes Project and clinical reference databases such as
Online Mendelian Inheritance in Man, and ClinVar. Delivering
excellent genomic coverage and high value content at an affordable
price, the Multi-Ethnic Array Family provides customers with the
power and pricing to effectively carry out studies across the
world’s populations.
Also at ASHG, Illumina will announce an Illumina Accelerator
Sequencing Grant competition available to applicants for the
incoming Illumina Accelerator genomic startup class. For more
information on the grant program, visit
www.illumina.com/science/accelerator/grant-competition.
For more information about the Illumina TruSeq Library
Preparation kits and Infinium Array product line, visit
www.illumina.com.
About Illumina, Inc.
Illumina is transforming human health as the global leader
in sequencing and array-based technologies. The company serves
customers in a broad range of markets, enabling the adoption of
genomic solutions in research and clinical settings. To learn
how Illumina is unlocking the power of the genome,
visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release may contain forward looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151007005141/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Eric
Endicott858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024